内容紹介
Summary
The characteristic adverse events of olaparib, a PARP inhibitor, are nausea, vomiting, and anemia, and interstitial pneumonia is rarely reported. We report a case of interstitial pneumonia following the treatment of a metastatic breast cancer with olaparib. The patient was a 34—year—old woman. In March 2018, she was diagnosed with stage Ⅳ breast cancer(multiple lung metastases). She was treated with epirubicin and cyclophosphamide followed by paclitaxel. In November 2018, brain and spinal cord metastases were detected, and she was treated with radiation. In December 2018, a BRCA1 deleterious mutation was confirmed, and treatment with olaparib was initiated. Six weeks later, olaparib was discontinued due to anemia;it also caused interstitial pneumonia. The interstitial pneumonia resolved following multidisciplinary treatment during hospitalization. Subsequently, she was treated with cyclophosphamide/methotrexate/fluorouracil. It is necessary to consider interstitial pneumonia as an adverse effect of olaparib.
要旨
Poly(adenosine diphosphate—ribose)polymerase(PARP)阻害剤であるolaparibの有害事象として嘔気や嘔吐,貧血は知られているが,間質性肺炎の報告はほとんどない。今回,olaparib投与後に間質性肺炎を発症した1例を報告する。症例は34歳,女性。2018年3月に右乳癌(T2N1M1,Stage Ⅳ,多発肺転移)の診断でepirubicin/cyclophosphamide療法,paclitaxel療法を行った。2018年11月に多発脳転移,脊髄転移の診断となり,全脳照射,脊髄照射を行った。遺伝子検査でBRCA1病的変異が明らかとなり,2018年12月よりolaparibを開始した。olaparib開始6週間後に貧血が出現,さらに間質性肺炎を認めた。入院の上,ステロイドを含んだ集学的治療を行い軽快退院した。現在は外来でCMF療法を行っている。乳癌に対するolaparibの有害事象として,まれではあるが間質性肺炎も考慮する必要がある。
目次
The characteristic adverse events of olaparib, a PARP inhibitor, are nausea, vomiting, and anemia, and interstitial pneumonia is rarely reported. We report a case of interstitial pneumonia following the treatment of a metastatic breast cancer with olaparib. The patient was a 34—year—old woman. In March 2018, she was diagnosed with stage Ⅳ breast cancer(multiple lung metastases). She was treated with epirubicin and cyclophosphamide followed by paclitaxel. In November 2018, brain and spinal cord metastases were detected, and she was treated with radiation. In December 2018, a BRCA1 deleterious mutation was confirmed, and treatment with olaparib was initiated. Six weeks later, olaparib was discontinued due to anemia;it also caused interstitial pneumonia. The interstitial pneumonia resolved following multidisciplinary treatment during hospitalization. Subsequently, she was treated with cyclophosphamide/methotrexate/fluorouracil. It is necessary to consider interstitial pneumonia as an adverse effect of olaparib.
要旨
Poly(adenosine diphosphate—ribose)polymerase(PARP)阻害剤であるolaparibの有害事象として嘔気や嘔吐,貧血は知られているが,間質性肺炎の報告はほとんどない。今回,olaparib投与後に間質性肺炎を発症した1例を報告する。症例は34歳,女性。2018年3月に右乳癌(T2N1M1,Stage Ⅳ,多発肺転移)の診断でepirubicin/cyclophosphamide療法,paclitaxel療法を行った。2018年11月に多発脳転移,脊髄転移の診断となり,全脳照射,脊髄照射を行った。遺伝子検査でBRCA1病的変異が明らかとなり,2018年12月よりolaparibを開始した。olaparib開始6週間後に貧血が出現,さらに間質性肺炎を認めた。入院の上,ステロイドを含んだ集学的治療を行い軽快退院した。現在は外来でCMF療法を行っている。乳癌に対するolaparibの有害事象として,まれではあるが間質性肺炎も考慮する必要がある。